CTLA4 and cancer: Although the development of autoimmune bullous diseases in cancer patients treated with ICIs is less likely to occur, the risk of the occurrence of bullous eruption in cancer patients treated with either PD-1 or PD-L1 inhibitors was higher than noted in cancer patients treated with CTLA-4 inhibitor [33,34,35,36].